• Latest Posts

French Biotech gets a Second Opportunity to Fight Liver Fibrosis

Genfit Delays Phase III Enrollment in the Race for the First NASH Therapy

Two Big Pharma Players Team up to Take Over the NASH Space

Why did Biotech Beat Pharma to Bring the First Gene Therapy to Market?

French Biotech gets a Boost in the NASH Race with a Successful IPO

Top European VC and CRO fund Young Metabolic Disease Biotech


Shire sells its RNA platform to a US-based Biotech

This British Biotech is buying its way into the Crowded NASH Space

The Largest Deals, Fundraising and Exits of 2016 in European Biotech

“We are Pioneering Cell Therapy to Cure NASH and Fibrotic Disease”

Green Light for Genfit to Tackle another Liver Disease

Novo Nordisk pressured into Dropping Needle-Free Oral Insulin